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The 2006 guidelines for treatment of life-threatening ven-tricular arrhythmias advocate device therapy for high-risk 
patients over drug therapy as primary strategy. Unsuccessful 
antiarrhythmic drug trials, together with positive implant-
able cardioverter-defibrillator trials, are at the basis of this 
approach. Despite successful device therapy, an unmet need 
for efficient drug therapy exists, for cost reasons as well as 
shock reduction and improved quality of life. Novel targets 
offer opportunities to revisit drug therapy.
Clinical Perspective on p 379
Remodeling in failure or compensated hypertrophy is often 
accompanied by action potential (AP) prolongation1 and sus-
ceptibility for repolarization-dependent arrhythmias. Calcium 
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Background—L-type calcium channel (LTCC) and Na+/Ca2+ exchanger (NCX) have been implicated in repolarization-
dependent arrhythmias, but also modulate calcium and contractility. Although LTCC inhibition is negative inotropic, 
NCX inhibition has the opposite effect. Combined block may, therefore, offer an advantage for hemodynamics 
and antiarrhythmic efficiency, particularly in diseased hearts. In a model of proarrhythmia, the dog with chronic 
atrioventricular block, we investigated whether combined inhibition of NCX and LTCC with SEA-0400 is effective 
against dofetilide-induced torsade de pointes arrhythmias (TdP), while maintaining calcium homeostasis and 
hemodynamics.
Methods and Results—Left ventricular pressure (LVP) and ECG were monitored during infusion of SEA-0400 and 
verapamil in anesthetized dogs. Different doses were tested against dofetilide-induced TdP in chronic atrioventricular 
block dogs. In ventricular myocytes, effects of SEA-0400 were tested on action potentials, calcium transients, and early 
afterdepolarizations. In cardiomyocytes, SEA-0400 (1 μmol/L) blocked 66±3% of outward NCX, 50±2% of inward 
NCX, and 33±9% of LTCC current. SEA-0400 had no effect on systolic calcium, but slowed relaxation, despite action 
potential shortening, and increased diastolic calcium. SEA-0400 stabilized dofetilide-induced lability of repolarization 
and suppressed early afterdepolarizations. In vivo, SEA-0400 (0.4 and 0.8 mg/kg) had no effect on left ventricular 
pressure and suppressed dofetilide-induced TdPs dose dependently. Verapamil (0.3 mg/kg) also inhibited TdP, but 
caused a 15±8% drop of left ventricular pressure. A lower dose of verapamil without effects on left ventricular pressure 
(0.06 mg/kg) was not antiarrhythmic.
Conclusions—In chronic atrioventricular block dogs, SEA-0400 treatment is effective against TdP. Unlike specific 
inhibition of LTCC, combined NCX and LTCC inhibition has no negative effects on cardiac hemodynamics.  
(Circ Arrhythm Electrophysiol. 2013;6:371-379.)
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channel antagonists, like the L-type calcium channel (LTCC) 
blocker verapamil, and magnesium sulfate2 can effectively 
treat torsade de pointes arrhythmias (TdP) in experimental and 
clinical settings,2–4 but are negative inotropic5,6 and, therefore, 
contraindicated in heart failure patients.
In this study, we explore whether combined LTCC and Na+/
Ca2+ exchanger (NCX) block by SEA-0400 is a potential anti-
arrhythmic strategy against early afterdepolarizations (EADs) 
and TdPs, which overcomes the negative inotropic effects of 
selective LTCC block by limiting Ca2+ efflux via NCX. Also, 
the NCX current has been implicated in EAD formation,7,8 and 
thus inhibition of NCX may add to the antiarrhythmic effect. 
Importantly, in the normal heart, SEA-0400 has no negative 
effects on [Ca2+]i,9,10 or even positive effects.9–11 The net effect 
of SEA-0400 in disease could be different because of dis-
turbed Ca2+ and Na+ balances.12
The antiarrhythmic potential of SEA-0400 is not completely 
established. In long QT syndrome models, data are contradic-
tory, with positive7,13,14 and negative results.15,16 Recently, SEA-
0400 was reported to be antiarrhythmic in failing rabbit hearts.17
The present study is the first to explore the combination of 
antiarrhythmic efficacy with the presumed neutral hemody-
namic effects of SEA-0400, in a model with high TdP sus-
ceptibility, the dog with chronic atrioventricular block (CAVB) 
and ventricular hypertrophy.18 Common calcium channel 
antagonists, despite antiarrhythmic potential, have limited 
usefulness because of negative inotropic effects. SEA-0400 
might be able to maintain hemodynamics and thus open cal-
cium channel block to wider clinical application. Its effects are 
compared with the classical calcium channel antagonist vera-
pamil, which is very effective in abolishing TdP.3
Materials and Methods
In Vivo Experiments
In 15 dogs 37 interventions were performed: 28 interventions for he-
modynamics or arrhythmia testing, 9 interventions for atrioventricu-
lar block creation without hemodynamic or arrhythmia study.
In a first series of tests (n=16), hemodynamic effects were deter-
mined by measuring left ventricular pressure (LVP) during infusion 
of verapamil or SEA-0400.
In the second series of tests (n=12), arrhythmias were induced us-
ing dofetilide, after which verapamil or SEA-0400 was infused as an 
antiarrhythmic.
For additional details, see online-only Data Supplement.
Cellular Experiments
Experiments were performed at 37°C in myocytes, enzymatically iso-
lated from the LV midmyocardial layer of CAVB hearts.19
Action potentials (APs) and membrane currents were recorded 
in the whole-cell patch clamp mode, with simultaneous record-
ing of Ca2+ signals in epifluorescence mode.20 See online-only Data 
Supplement for protocols and solutions.
SEA-0400 Plasma Concentrations
Blood samples were collected through a venous catheter every 5 minutes 
during experiment. Heparin-treated samples were centrifuged at 1300 
rcf and stored at −80°C for further analysis. Concentrations of SEA-
0400 were determined by high-performance liquid chromatography.
Statistics
For cellular data, paired t test or 1-way ANOVA for repeated mea-
surements (Bonferroni post test) was performed as appropriate. For 
the in vivo data, 1-way repeated measures ANOVA was combined 
with a post hoc Holm–Sidak analysis. In vivo data are presented as 
mean±SD, N values are number of dogs. For cellular data mean±SE 
are shown, n values are numbers of cells.
Results
Quantification of NCX and LTCC Block by  
SEA-0400
We quantified the effect of 1 µmol/L SEA-0400 on NCX-
mediated currents (INCX) and inward Ca2+ current mediated 
through LTCC (ICaL) in CAVB myocytes.
INCX was measured as the Ni2+ sensitive current during volt-
age ramps, at constant [Na+]i (10 mmol/L) and [Ca2+]i (≈100 
nmol/L free Ca2+; Figure 1A). SEA-0400 inhibited 66±3% of 
outward and 50±2% of inward INCX (n=5; Figure 1B).
ICaL was measured during a depolarizing step to +10 mV 
(low sarcoplasmic reticulum [SR] Ca2+ load, 0.1 Hz repletion 
rate; Figure 1C). ICaL block by SEA-0400 was 33±9% (n=6; 
Figure 1D), comparable with values reported in a previous 
study in which we characterized SEA-0400 effects over a 
wider voltage range.12 Note the reduced inward tail current 
on repolarization (Figure 1E-a), despite higher [Ca2+]i levels 
(Figure 1E-b, c), which reflects forward NCX block (n=4; 
Figure 1E-d). Despite partial LTCC block, peak and amplitude 
of the Ca2+ transient were increased.
SEA-0400 Effects on AP and [Ca2+]i
The effect of SEA-0400 on [Ca2+]i and APs is illustrated in 
Figure 2A. Red traces were recorded when wash-in of SEA-
0400 had reached steady state. SEA-0400 had no effects on 
peak [Ca2+]i, but increased diastolic [Ca2+]i, slowed relaxation, 
and shortened action potential duration (APD) (Figure 2). 
We also recorded Ca2+ transients and APs during wash-out 
(blue traces). We have previously observed that LTCC block 
by SEA-0400 was rapidly reversible on wash-out, whereas 
NCX block was not.12 The removal of LTCC inhibition had 
pronounced effects on the Ca2+ transients during wash-out. 
There was a 2-fold increase of peak [Ca2+]i, further impair-
ment of relaxation, and a larger increase of diastolic [Ca2+]i. 
APs relengthened (n=5; Figure 2B).
These data illustrate that partial NCX block causes a net 
gain of Ca2+, which is counterbalanced by reduced ICaL during 
combined block. The changes in AP may contribute to these 
changes in Ca2+ balance.
Effects of SEA-0400 on EADs and APD
Figure 3A shows a typical experiment testing effects of SEA-
0400 against dofetilide-induced EADs in a CAVB cell, and 
Figure 3B shows beat-to-beat changes in APD and short-
term variability (STV, red line) of repolarization, a marker 
of proarrhythmia. Typically, dofetilide prolonged AP and 
increased STV. SEA-0400 was applied after the first EAD 
appeared. In all cells (n=11), SEA-0400 suppressed EADs 
and restored STV (Figure 3C). In Figure 3D, we plotted 
individual data of STV in function of APD. This revealed 
a positive relation between STV and AP prolongation in 
the presence of dofetilide; SEA-0400 caused a downward 
shift of this curve. In a subset of cells (n=5), we monitored 
changes in [Ca2+]i during wash-in of dofetilide and SEA-0400 
(Figure 3E). Dofetilide alone increased peak and amplitude 
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of the Ca2+ transient. SEA-0400 caused a further increase of 
diastolic, but not peak [Ca2+]i; the amplitude was comparable 
with baseline.
SEA-0400 Preserves LVP, While Verapamil  
Is Negative Inotropic
Before antiarrhythmic testing, we examined baseline effects 
of SEA-0400 in anesthetized sinus rhythm and CAVB dogs. 
CAVB dogs have lower heart rates, prolonged QT, and 
higher LVP. SEA-0400 was administered in cumulative doses 
>5-minute infusion period, to a final dose of 0.4 or 0.8 mg/kg. 
This resulted in peak plasma concentrations of 5±1 and 11±2 
μmol/L at 5 minutes after the start of infusion, and 1.5±0.3 
and 4.2±0.5 μmol/L at 10 minutes (n=3–7). Neither SEA-
0400 dose had an effect on heart rate, QT time, STV-QT nor 
diastolic and maximal LVP (Table).
In Figure 4, the relative change of LVP during infusion of 
SEA-0400 was compared with verapamil. At a cumulative 
dose of 0.3 mg/kg, verapamil caused a 15% drop in systolic 
LVP, with no effects on HR, QT, or baseline STV (Table). 
On the basis of this dose–pressure response (Figure 4), 2 
dosages of verapamil were chosen for antiarrhythmic testing: 
a hemodynamically neutral (0.06 mg/kg) and a negative 
inotropic dose (0.3 mg/kg). Absolute changes in LVP can be 
found in the Table for both SR and CAVB dogs; CAVB dogs 
are known to have a higher baseline LVP.
SEA-0400 Suppresses TdP, While Preserving LVP
Dofetilide induced TdP in 6 of 9 dogs (67%; Figure 5A). TdPs 
were suppressed by verapamil and SEA-0400 (Figure 5B 
and 5C). Dofetilide caused QT prolongation and increased 
STV-QT. Subsequent administration of a low dose of 
with a post hoc Holm–Sidak analysis. In vivo data are presented as 
mean±SD, N values are number of dogs. For cellular data mean±SE 
are shown, n values are numbers of cells.
Results
Quantification of NCX and LTCC Block by  
SEA-0400
We quantified the effect of 1 µmol/L SEA-0400 on NCX-
mediated currents (INCX) and inward Ca2+ current mediated 
through LTCC (ICaL) in CAVB myocytes.
INCX was measured as the Ni2+ sensitive current during volt-
age ramps, at constant [Na+]i (10 mmol/L) and [Ca2+]i (≈100 
nmol/L free Ca2+; Figure 1A). SEA-0400 inhibited 66±3% of 
outward and 50±2% of inward INCX (n=5; Figure 1B).
ICaL was measured during a depolarizing step to +10 mV 
(low sarcoplasmic reticulum [SR] Ca2+ load, 0.1 Hz repletion 
rate; Figure 1C). ICaL block by SEA-0400 was 33±9% (n=6; 
Figure 1D), comparable with values reported in a previous 
study in which we characterized SEA-0400 effects over a 
wider voltage range.12 Note the reduced inward tail current 
on repolarization (Figure 1E-a), despite higher [Ca2+]i levels 
(Figure 1E-b, c), which reflects forward NCX block (n=4; 
Figure 1E-d). Despite partial LTCC block, peak and amplitude 
of the Ca2+ transient were increased.
SEA-0400 Effects on AP and [Ca2+]i
The effect of SEA-0400 on [Ca2+]i and APs is illustrated in 
Figure 2A. Red traces were recorded when wash-in of SEA-
0400 had reached steady state. SEA-0400 had no effects on 
peak [Ca2+]i, but increased diastolic [Ca2+]i, slowed relaxation, 
and shortened action potential duration (APD) (Figure 2). 
We also recorded Ca2+ transients and APs during wash-out 
(blue traces). We have previously observed that LTCC block 
by SEA-0400 was rapidly reversible on wash-out, whereas 
NCX block was not.12 The removal of LTCC inhibition had 
pronounced effects on the Ca2+ transients during wash-out. 
There was a 2-fold increase of peak [Ca2+]i, further impair-
ment of relaxation, and a larger increase of diastolic [Ca2+]i. 
APs relengthened (n=5; Figure 2B).
These data illustrate that partial NCX block causes a net 
gain of Ca2+, which is counterbalanced by reduced ICaL during 
combined block. The changes in AP may contribute to these 
changes in Ca2+ balance.
Effects of SEA-0400 on EADs and APD
Figure 3A shows a typical experiment testing effects of SEA-
0400 against dofetilide-induced EADs in a CAVB cell, and 
Figure 3B shows beat-to-beat changes in APD and short-
term variability (STV, red line) of repolarization, a marker 
of proarrhythmia. Typically, dofetilide prolonged AP and 
increased STV. SEA-0400 was applied after the first EAD 
appeared. In all cells (n=11), SEA-0400 suppressed EADs 
and restored STV (Figure 3C). In Figure 3D, we plotted 
individual data of STV in function of APD. This revealed 
a positive relation between STV and AP prolongation in 
the presence of dofetilide; SEA-0400 caused a downward 
shift of this curve. In a subset of cells (n=5), we monitored 
changes in [Ca2+]i during wash-in of dofetilide and SEA-0400 
(Figure 3E). Dofetilide alone increased peak and amplitude 
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Figure 1. Block of Na+/Ca2+ exchanger (NCX) and ICaL by SEA-0400. A, NCX currents sensitive to 5 mmol/L Ni
2+ (total INCX, black) and 1 
μmol/L SEA-0400 (red) during repolarizing ramps (step from −40 to +80 mV, descending ramp to −120 mV in 2 s; averaged current traces 
of 5 cells). B, Fraction of total INCX blocked by 1 μmol/L SEA-0400. Outward and inward INCX were calculated at 60 mV on either side of the 
reversal potential. C, Example of ICaL and Ca
2+ transients recorded during a depolarizing step to +10 mV before and after 1 μmol/L SEA-
0400. INa was inactivated by a prepulse to −40 mV, and currents were recorded in K
+ and EGTA-free solutions. D, ICaL amplitude under 
baseline and with SEA-0400 (n=6). E, Pooled data of NCX tail current density (a) and [Ca2+]i (b) on repolarization to −70 mV; (c) INCX nor-
malized to [Ca]2+; (d) percentage of NCX tail current block at −70 mV (n=4, *P<0.05, paired t test).
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verapamil did not suppress TdPs (11±6 episodes per 5 min-
utes versus 12±7), whereas the higher dose was completely 
effective (0 TdPs). This was associated with reduced STV-QT, 
without shortening QT time (Figure 5A, lower graph). These 
parameters could not be determined at the low dose of vera-
pamil because arrhythmias interfered with measurements.
SEA-0400 was antiarrhythmic (Figure 5C) with a dose-
dependent effect: 0.4 mg/kg partially suppressed (from 7±4 
to 3±4 episodes per 5 minutes), and 0.8 mg/kg completely 
abolished TdPs. The partial antiarrhythmic effect of 0.4 
mg/kg SEA-0400 did not prevent occurrence of extra beats, 
which excluded reliable STV-QT measurements. At 0.8 mg/
kg, SEA-0400 tended to reduce STV-QT and had no effect on 
dofetilide-induced QT prolongation.
Discussion
Our data show that SEA-0400, a NCX blocker with addi-
tional LTCC inhibition, is an effective antiarrhythmic against 
dofetilide-induced EADs and TdPs. It has an advantage over 
primary block of LTCC with verapamil, another efficient anti-
arrhythmic, because of the lack of negative inotropy at equal 
antiarrhythmia efficacy.
Clinical Need for New Drugs in Heart Failure
With aging of the population and improved postinfarction 
survival, the number of patients treated for arrhythmias 
is increasing. Especially in the group with heart failure, 
there is a growth in number of implantable cardioverter-
defibrillator implants. In recent years, new antiarrhythmic 
drugs have been tested to relieve the burden of implant-
able cardioverter-defibrillator shock: adjunct therapy. Until 
now, these trials with azimilide21 and celivarone22 have been 
insufficiently successful for a broad clinical implication. In 
part this can be attributed to the limitations in dosage of 
the applied drugs because of adverse effects, based either 
on proarrhythmia or on negative inotropism. Therefore, 
there is an unmet need to develop new drugs that are devoid 
of adverse actions and can be applied in these patient 
populations.
CAVB Dog Model
Induction of chronic, complete atrioventricular block results 
in ventricular remodeling and encompasses molecular and 
cellular changes at the electric, contractile (enhanced Ca2+ 
transient), and structural level.18 In the CAVB dog, the ben-
eficial adaptations that lead to compensated biventricular 
hypertrophy are counteracted by TdP susceptibility in vivo 
(eg, incidence with dofetilide, 75%) and EADs in vitro.3,19 
The model is, therefore, suited to address the question how 
an antiarrhythmic action of SEA-0400 can be combined with 
maintained LV contractile performance.
Comparison With Other Antiarrhythmics  
in the CAVB Dog
Over the years, numerous antiarrhythmics have been tested in 
this model. Considering possible confounding influences as 
drug dosage and duration of administration, 3 categories of 
action can be identified:
1. Ca2+ antagonists, verapamil and flunarizine, are very ef-
fective agents that prevent and suppress TdP and EADs.
2. Ranolazine and lidocaine suppress about 60% of the 
drug-induced TdP. Late sodium current inhibition is 
effective, although the current density was reduced in 
CAVB dogs as compared with SR.19 We have also found 
that subsarcolemmal [Na+] is increased in this model re-
lated to altered Na/K pump function.23 This is also of 
importance in identifying the effects of SEA-0400, as 
higher sodium concentrations promote NCX reverse 
Table. Electrophysiological and Left Ventricular Pressure Changes After SEA-0400 and Verapamil Infusion
Sinus Rhythm Chronic AVB Chronic AVB
SEA-0400
 Dose 0 mg 0.4 mg 0 mg 0.4 mg 0 mg 0.8 mg
 HR 95±25 92±27 43±6 42±6 28±15 36±11
 QT 264±28 267±31 424±105 411±85 406±48 434±35
 QT-STV 1±1 1±1 11±5 11±5 8±7 6±6
 LVP
sys 96±21 96±20 90±13 90±14 82±28 85±18
 LVP
diast 3±1 3±1 7±8 5±8 13±12 13±12
 N 3 3 3 3 4 4
Verapamil
 Dose 0 mg 0.3 mg 0 mg 0.3 mg
 HR 101±9 100±15 42±7 43±5
 QT 302±15 304±18 551±59 558±41
 QT-STV 0.5±0.2 0.5±0.2 11±6 9±5
 LVP
sys 70±7 54±4* 97±4 89±2*
 LVP
diast 4±3 4±2 9±1 7±2
 N 3 3 3 3
Parameters were determined after 5-min infusion of SEA-0400 to a final dose of 0.4 mg/kg (sinus rhythm and CAVB dogs) and 0.8 mg/kg (CAVB dogs only), and 
verapamil (0.3 mg/kg). AVB indicates atrioventricular block; HR, heart rate (beats per minute); LVP
diast and LVPsys, diastolic and systolic left ventricular pressure (mm Hg); 
N, no. of animals; and QT-STV, QT and short-term variability of QT interval (ms). *P<0.05 vs baseline (0 mg/kg).
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mode and enhance SEA-0400 NCX block. In the CAVB 
dog, forward and reverse NCX are increased.24
3. Drugs, such as K201 and AVE0118, were not effective at 
all in controlling these arrhythmias.
The superior antiarrhythmic action of Ca2+ antagonists is, 
however, accompanied by reduced LV (−26%) and systolic 
blood pressure (−27%) with flunarizine (2 mg/kg),25 whereas 
0.3 mg/kg verapamil (this study) lowered LVP by 15%. In 
contrast, the SEA-0400 dosage could be increased to 0.8 mg/
kg to have 100% efficacy without compromising LV function.
Mechanisms of Antiarrhythmic Activity  
of SEA-0400
The antiarrhythmic effect of SEA-0400 was linked to reduced 
beat-to-beat variability (STVQT or STVAPD), whereas it did not 
shorten QT time or APD. The link between variability and 
TdPs has been well established.3 Similarly, verapamil also 
did not shorten the QT interval, but decreased STVQT and 
STVLV MAPD,3 suggesting that LTCC block is involved in reduc-
ing STV and net inward current during the AP plateau. This 
may directly reduce the likelihood of EADs, related to reacti-
vation of LTCC.
Furthermore, in the absence of dofetilide, the inhibition 
by SEA-0400 is responsible for some AP shortening 
(Figure 2). In the presence of dofetilide, this shortening is no 
longer apparent, yet STV is reduced. The lack of shortening 
may be because of the predominant effect of dofetilide, 
but the shift in balance of currents during the AP plateau, 
favoring repolarization because of reduced inward current, is 
presumably still present and thus reduces variability.
Reduced NCX current by itself could also contribute to the 
observed effects. The role of NCX in EADs is less equivocal 
than in delayed afterdepolarizations (DADs), but several 
lines of evidence support its contribution.26 The reduced 
variability can also be partly ascribed to Ca2+-dependent acti-
vation of NCX during the AP plateau, as intracellular [Ca2+]i 
buffering reduces STV after IK block.13
SEA-0400 may exert its effects via forward and reverse 
mode block of NCX as it blocks both modes equally in dog 
myocytes. This is not unique to the dog, but has previously 
also been shown in pig and mouse12 and in guinea pig.27
In summary, both NCX and the LTCC inhibition contribute 
to the antiarrhythmic effect of SEA-0400. This mechanism of 
action complements reported effects of SEA-0400 on DADs 
through NCX block in isoproterenol-induced arrhythmias.28 
Preliminary data suggest that in the CAVB dog, SEA-0400 is 
also effective on afterdepolarizations related to spontaneous 
Ca2+ release.
Mechanism of Preserved LV Function: Calcium 
Balance
In pig and mouse myocytes, SEA-0400 induced a Ca2+ tran-
sient12 increase, whereas others have demonstrated variable 
effects in dog and rabbit.7,17 The data underscored that SEA-
0400 effects will depend on the prevailing Ca2+ fluxes and 
balance between LTCC, Ca2+ influx and removal by NCX, 
and SR Ca2+ release and reuptake. This is supported by the 
observation that in 2 mouse models of disease (hypertrophy 
and heart failure), the net effect on Ca2+ handling was differ-
ent from that in healthy hearts.12 In the hypertrophic remodel-
ing consequent to CAVB, SEA-0400 during 1 Hz pacing did 
not increase the [Ca2+]i transient amplitude, although diastolic 
Ca2+ increased slightly.
Using the different kinetics of SEA-0400 for LTCC and 
NCX, we could demonstrate that the effect of SEA-0400 is the 
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Figure 2. Effects of SEA-0400 on action potential 
(AP) and Ca2+ transients. A, Example of APs (top) and 
Ca2+ transients (bottom), under baseline (black), 1 
μmol/L SEA-0400 (red) and during wash-out (blue), 
in a chronic atrioventricular block cell at 1 Hz. B, 
Pooled data of APD90. C, Diastolic and peak [Ca
2+]i, 
and Ca transient amplitude (peak-baseline). D, Kinet-
ics of Ca2+ transient. TTP indicates time-to-peak; 
RT50, time to half maximal relaxation. *P<0.05 vs 
baseline, # vs SEA-0400 (ANOVA for repeated mea-
surements, n=5 cells).
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net result of reduced Ca2+ release because of LTCC inhibition 
and gain of Ca2+ through inhibition of NCX. Shortening of the 
AP with the LTCC inhibition also contributes to maintaining 
Ca2+ balance, as a net gain can be observed under voltage 
clamp (data not shown).
LTCC inhibition is partially inherent to the properties of 
SEA-0400 (Figure 1C). However, LTCC inhibition is fur-
ther enhanced by reduced removal of Ca2+ consequent on 
NCX inhibition. This property may be favorable in protecting 
against Ca2+ overload at higher heart rates.
The cellular data are in line with the preservation of LVP in 
vivo. However, SEA-0400 did increase diastolic [Ca2+]i after 
dofetilide treatment. Data from another study have linked this to 
diastolic dysfunction.29 In the present study, we did not observe 
an increase in diastolic pressure. This may be explained by 
the fact that diastolic function is only partially dependent on 
relaxation of the myocyte Ca2+ transient.30 Also, vasodilata-
tion leads to lower diastolic pressures, which may be part of 
SEA-0400 action (see patent: 7183322 Remedy for hyperten-
sion). However, we could not directly assess the effect of vaso-
dilatation on cardiac function, as we only measured pressure, 
not output. So far, the effects of SEA-0400 on cardiac output 
are unknown.
Under control conditions the effects of SEA-0400 on dia-
stolic pressure (Table) was negligible, as previously reported,11 
neither did we see effects on relaxation, quantified as –LV dP/
dt (data not shown).
Caveats and Safety Limitations for Use of SEA-0400
NCX and LTCC are also modulators of Ca2+ balance in cells 
other than cardiomyocytes, like smooth muscle cells.
Another potential side effect of LTCC blocking drugs is 
interference with atrioventricular conduction. In CAVB this 
is difficult to determine, but in 3 dogs that received SEA-
0400 before atrioventricular block in sinus rhythm, heart 
rate (Table) and atrioventricular conduction (P-R interval 
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Figure 3. Antiarrhythmic effects of 
SEA0400 against early afterdepolarizations 
(EADs). A, Recordings of action potentials 
(APs) at 0.5 Hz in a chronic atrioventricular 
block cell showing dofetilide-induced EADs 
and suppression by SEA-0400 (1 μmol/L). 
B, Time-dependent changes in APD90 (sym-
bols), short-term variability (STV; red line) 
and EADs during wash-in of dofetilide and 
SEA-0400. C, Pooled data of APD90 (left) 
and STV (right) of 11 cells. For dofetilide, 
APD and STV values are an average of 
30 successive beats before the first EAD 
(*P<0.05). D, Individual data of STV in 
function of APD90. E, Parameters of Ca
2+ 
transients during the different treatments; 
averaged data of 5 cells (*P<0.05 vs base-
line; ANOVA for repeated measurements).
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went from 110±6 to 108±12) were not affected. Other 
authors31 have reported atrioventricular block and cardiac 
stand still after SEA-0400 infusion, but at a 3.75× higher 
dose, indicating a dose-dependent safety limit.
The promising results of the present study should not be 
directly transposed to arrhythmias in other disease models. The 
CAVB dog is a model for compensated hypertrophy, not heart 
failure. Others’ results with SEA-0400 were mixed: positive in 
an isolated rabbit heart model of TdP induced with veratridine 
or sotalol,14 but not with dofetilide.16 In models of coronary 
occlusion, arrhythmias were reduced in rat,32 but not in dog.31 
In the guinea pig treated with aconitine, SEA-0400 was not 
effective.15 None of these were studies of chronic disease. Given 
the delicate balance of Ca2+ and the different adaptations in, for 
example, ischemic cardiomyopathy or pressure overload, this will 
need further study.
Another complicating factor could be the change of the 
calcium flux with different heart rates (eg, with adrenergic 
stimulation). The CAVB dog has an unnatural low beating 
frequency (Table) and one must be careful in extrapolating 
these results to situations with higher heart rates.
Also, the dose of SEA-0400 has to be taken into account. In 
our experiments, we went up to 0.8 mg/kg to achieve efficacy 
against TdP without adverse hemodynamic effects. Whether 
the dose can be further increased is not known and of interest 
for further studies.
Lastly, it should be taken into account that administration 
of SEA-0400 did increase diastolic calcium levels. Long-term 
application could potentially lead to the activation of calcium-
dependent signaling proteins like calcineurin, which might 
lead to detrimental cardiac remodeling.
Perspectives
The concept of multiple targets in antiarrhythmic drugs is not 
new and has been used to improve efficacy or minimize side 
effects. The advantage of SEA-0400 is that it is a de facto 
coinhibitor, composed into 1 drug and its targets are known 
culprits in arrhythmogenesis.
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Figure 4. Relative pressure changes during 
verapamil or SEA-0400 infusion. A, Exam-
ples of left ventricular pressure (LVP) curves 
during verapamil of SEA-0400 treatment. 
Lead II was inserted for reference. P-waves 
are denoted with grey arrows. Note that, 
as these are chronic atrioventricular block 
dogs, P-waves and QRS complexes do not 
correlate. The blue dashed lines indicate 
the maximum pressure of the curves at 
baseline. B, Relative changes of systolic 
LVP during cumulative infusion of (▼) 
verapamil, 0.3 mg/kg per 5 min (N=6); (○) 
SEA-0400, 0.4 mg/kg per 5 min (N=6); (● ) 
SEA-0400 0.8 mg/kg per 5 min (● ; N=4). 
Arrow depicts the highest cumulative dose 
of verapamil without effect on pressure 
(hemodynamic neutral dose, 0.06 mg/kg).
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In short, the dual block of NCX and LTCC has promise as 
a safe and effective strategy against repolarization-dependent 
arrhythmias, with on top of that the important benefit of pre-
served hemodynamics.
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CLINICAL PERSPECTIVE
Despite successful device therapy to treat life-threatening arrhythmias, an unmet need for efficient drug therapy exists. 
Such drugs should protect against arrhythmias without negative inotropic effects. In the present study, we tested SEA-0400, 
a drug that inhibits the Na+/Ca2+ exchanger and the L-type Ca2+ channel, 2 pathways involved in arrhythmogenesis and in 
contractility. In the dog with chronic AV block, a model for arrhythmias in the hypertrophied heart, we show that SEA-0400 
is effective and superior to L-type Ca2+ channel block alone. Moreover, SEA-0400 suppressed evoked torsades de pointes 
dose dependently without affecting hemodynamics. In isolated cells, SEA-0400 was also effective in suppressing the cellular 
action potential prolongation and afterdepolarizations. These data indicate that the dual block of NCX and LTCC has prom-
ise as a safe and effective strategy against repolarization-dependent arrhythmias, with the important benefit of preserved 
hemodynamics. Additional studies should evaluate this approach in heart failure where Na+/Ca2+ exchange is upregulated, 
and maintained hemodynamics are even more important.
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